Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Insmed's operating assets for the quarter that ended in Dec. 2023 was $549.4 Mil. Insmed's operating liabilities for the quarter that ended in Dec. 2023 was $457.8 Mil. Insmed's Total Assets for the quarter that ended in Sep. 2023 was $1,324.9 Mil. Therefore, Insmed's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.07.
Insmed Scaled Net Operating Assets Historical Data
The historical data trend for Insmed's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Insmed Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Scaled Net Operating Assets |
|
|
|
|
|
|
0.28 |
0.20 |
0.38 |
0.10 |
0.06 |
|
Insmed Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Scaled Net Operating Assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.12 |
0.09 |
0.08 |
0.09 |
0.07 |
Competitive Comparison
For the Biotechnology subindustry, Insmed's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insmed Scaled Net Operating Assets Distribution
For the Biotechnology industry and Healthcare sector, Insmed's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Insmed's Scaled Net Operating Assets falls into.
Insmed Scaled Net Operating Assets Calculation
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Insmed's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as
| Scaled Net Operating Assets (SNOA) | | (A: Dec. 2023 ) |
| = | (Operating Assets (A: Dec. 2023 ) | - | Operating Liabilities (A: Dec. 2023 )) | / | Total Assets (A: Dec. 2022 ) |
| = | (549.39 | - | 457.766) | / | 1656.435 |
| = | 0.06 |
where
Insmed's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as
| Scaled Net Operating Assets (SNOA) | | (Q: Dec. 2023 ) |
| = | (Operating Assets (Q: Dec. 2023 ) | - | Operating Liabilities (Q: Dec. 2023 )) | / | Total Assets (Q: Sep. 2023 ) |
| = | (549.39 | - | 457.766) | / | 1324.873 |
| = | 0.07 |
where
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insmed (Insmed) Business Description
Traded in Other Exchanges
Address
700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
Executives
| Flammer Martina M.d. |
officer: Chief Medical Officer |
700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807 |
| Roger Adsett |
officer: Chief Commercial Officer |
10 FINDERNE AVENUE, BRIDGEWATER NJ 08807 |
| John Drayton Wise |
officer: Chief Commercial Officer |
700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807 |
| Michael Alexander Smith |
officer: General Counsel, Senior VP |
700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807 |
| William Lewis |
officer: President & CEO |
10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807 |
| Schaeffer Orlov S Nicole |
officer: Chief People Strategy Officer |
INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807 |
| Sara Bonstein |
officer: Chief Financial Officer |
305 COLLEGE ROAD EAST, PRINCETON NJ 08540 |
| Melvin Md Sharoky |
director |
10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807 |
| Leo Lee |
director |
10 FINDERNE AVENUE, BRIDGEWATER NJ 08807 |
| David R Brennan |
director |
C/O INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807 |
| Steinar J Engelsen |
director |
10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807 |
| John Soriano |
officer: Chief Compliance Officer |
10 FINDERNE AVENUE, BRIDGEWATER NJ 08807 |
| Christine A Pellizzari |
officer: General Counsel & Secretary |
10 FINDERNE AVENUE, BRIDGEWATER NJ 08807 |
| Alfred Altomari |
director |
C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540 |
| Elizabeth M Anderson |
director |
10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807 |
Insmed (Insmed) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INSM has been successfully added to your